<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04275219</url>
  </required_header>
  <id_info>
    <org_study_id>001/20180101</org_study_id>
    <nct_id>NCT04275219</nct_id>
  </id_info>
  <brief_title>Based on the &quot;Brain-gut -Lung&quot; Axis, the Mechanism of Treating Stroke-associated Pneumonia by Tong-Fu-Xing-Shen Capsules</brief_title>
  <acronym>SAPTFXS</acronym>
  <official_title>Based on the &quot;Brain-gut -Lung&quot; Axis, the Mechanism of Treating Stroke-associated Pneumonia by Tong-Fu-Xing-Shen Capsules（MTSAPTFXS）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ganzhou People's Hospital Affiliated to Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lianjiang Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yangjiang Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The regulation of γδ T cells / IL-17 pathway mediated by the intestinal flora has become a
      new molecular target for the treatment of SAP. To test whether TFXSCs are through the pathway
      as above, this protocol describes an ongoing randomized controlled clinical trial, based on
      the theory of traditional Chinese medicine（TCM）.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total
      of 378 patients will be recruited and randomly assigned to TFXSCs group or placebo-matched
      group in a 1:1 ratio. The treatment course is 10-12 consecutive days, with a 90±7-day
      follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change of lymphocytes like γ δ T cells, Treg cells in peripheral blood and sputum</measure>
    <time_frame>90 days</time_frame>
    <description>the frequency of γ δ T cells, Treg cells is measured by flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of peripheral inflammatory markers such as IL-17, IL-23, IL-10 in serum and in sputum supernatant</measure>
    <time_frame>90 days</time_frame>
    <description>the quantitative of cytokine is tested by liquid chips</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in the gut microbiota</measure>
    <time_frame>90 days</time_frame>
    <description>gut microbiota is monitored via 16S rRNA gene sequence analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS scoring scale</measure>
    <time_frame>90 days</time_frame>
    <description>NIHSS scoring scale for neurological impairment assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke scale quality of life（SS-QOL）</measure>
    <time_frame>90 days</time_frame>
    <description>SS-QOL for quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BI index</measure>
    <time_frame>90 days</time_frame>
    <description>BI index for living ability assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale (mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>mRS for the degree of dependence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">378</enrollment>
  <condition>Stroke</condition>
  <condition>Complication</condition>
  <arm_group>
    <arm_group_label>Tongfu capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tongfu capsules prescription (0.4g*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The Placebo of Tongfu capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Placebo of Tongfu capsules prescription (0.4g*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tongfu capsules</intervention_name>
    <description>Tongfu capsules include 5 herbals</description>
    <arm_group_label>Tongfu capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The Placebo of Tongfu capsules</intervention_name>
    <description>The Placebo of Tongfu capsules are made from dextrin, starch and so on.</description>
    <arm_group_label>The Placebo of Tongfu capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of spontaneous haemorrhage according to Western medicine, CT scan of brain
             confirmed acute intracerebral hemorrhage;

          2. Aged between 18 and 85;

          3. Diagnosis of modified CDC;

          4. within 7 days after stroke onset;

          5. Willingness to participate and to sign the informed consent form.

        Exclusion Criteria:

          1. Cerebral hemorrhage is confirmed by examination to be caused by a brain tumor, brain
             trauma, blood disease, cerebrovascular malformation (a congenital abnormality) or
             aneurysm;

          2. Patients with a cerebral hernia;

          3. GCS＜7;

          4. Received any antibiotic treatment within 4 weeks before the start of the study;

          5. Patients with pulmonary tuberculosis, pulmonary edema, pulmonary embolism,
             non-infectious pulmonary itomy and respiratory circulation failure;

          6. Patients with liver or kidney function (such as alanine aminotransferase [ALT],
             aspartate aminotransferase [AST] and creatinine[Cre]) 3 times higher than the normal
             upper limit;

          7. Patients with a clear history of gastrointestinal diseases such as gastrointestinal
             tumors, inflammatory bowel disease, a gastrointestinal bleeding period within 3
             months;

          8. Patients with immune-related diseases such as SLE, rheumatoid arthritis, sjogren's
             syndrome or receiving immunotherapy for other diseases;

          9. Patients who are not suitable for the trial as decided by the researchers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianwen Guo, doctor</last_name>
    <phone>0086-13724899379</phone>
    <email>jianwen_guo@msn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>jianwen Guo, MD</last_name>
    <phone>(08620)81887233</phone>
    <phone_ext>30906</phone_ext>
    <email>306247680@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Province Hospital of Tradtional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianwen Guo, Dr</last_name>
      <phone>020-81887233</phone>
      <phone_ext>34530</phone_ext>
      <email>jianwen_guo@msn.com</email>
    </contact>
    <investigator>
      <last_name>Jianwen Guo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>May 23, 2020</last_update_submitted>
  <last_update_submitted_qc>May 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke-associated pneumonia</keyword>
  <keyword>Tong-Fu-Xing-Shen capsules</keyword>
  <keyword>traditional Chinese medicine</keyword>
  <keyword>Brain-gut-lung axis</keyword>
  <keyword>Randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

